Bcr/Abl associated leukemogenesis in bcr null mutant mice
Jan Willem Voncken+3 more
openalex +1 more source
Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]
Paciaroni K+8 more
europepmc +1 more source
Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. [PDF]
Ayalew ZS+8 more
europepmc +1 more source
Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells [PDF]
Alec W. Gross, Ruibao Ren
openalex +1 more source
Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells. [PDF]
Yang L+5 more
europepmc +1 more source
Specific human cellular immunity to bcr-abl oncogene-derived peptides
Monica Bocchia+6 more
openalex +1 more source
The Effect of Bcr-Abl Protein Tyrosine Kinase on Maturation and Proliferation of Primitive Haematopoietic Cells [PDF]
Anne‐Marie Buckle+6 more
openalex +1 more source
Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis. [PDF]
Sanches VHDS+11 more
europepmc +1 more source